Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer

Cancer Letters

Volumn 199, Issue 1, 2003, Pages 99-105

  Shih, Chuen Ming ^a,b   Hsu, Wu Huei ^a   Huang, Wen Tao ^c   Wang, Jhi Joung ^d   Ho, Shung Tai ^e   Kao, Albert ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c YUANPEI UNIVERSITY   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Lung resistance related protein; Non small cell lung cancer; P glycoprotein; Single photon emission computed tomography; Taxol; Technetium 99m methoxyisobutylisonitrile

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; TRACER;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG PROTEIN BINDING; DRUG UPTAKE; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX RADIOGRAPHY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR BIOPSY; WEIGHT REDUCTION;

EID: 0041878843     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00335-5     Document Type: Article

References (31)

1. Akiyama S., Chen Z.S., Kitazono M., Sumizawa T., Furukawa T., Aikou T. Mechanisms for resistance to anticancer agents and the reversal of the resistance. Hum. Cell. 12:1999;95-102.
2. Alberola V., Rosell R., Gonzalez-Larriba J.L., Molina F., Ayala F., Garcia-Conde J., Benito D., Perez J.M. Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer. Ann. Oncol. 6:1995;S49-S52.
3. Arbuck S.G., Dorr A., Friedman M.A. Paclitaxel (Taxol) in breast cancer. Breast Cancer. 8:1994;121-140.
4. Cheng S.H., Lam W., Lee A.S.K., Fung K.P., Wu R.S., Fong W.F. Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution. Toxicol. Appl. Pharmacol. 164:2000;134-142.
5. Chiu M.L., Kronauge J.F., Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblast. J. Nucl. Med. 31:1990;1446-1453.
6. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistance human lung cancer cell line. Science. 258:1992;1650-1654.
7. Crankshaw C.L., Marmion M., Luker G.D., Rao V., Dahlheimer J., Burleigh B.D., Webb E., Deutsch K.F., Piwnica Worms D. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein. J. Nucl. Med. 39:1998;77-86.
8. Dingemans A.M.C., van Ark-Otte J., van der Valk P., Apolinario R.M., Scheper R.J., Postmus P.E., Giaccone G. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann. Oncol. 7:1996;625-630.
9. Donebower R.C., Rowinsky E.K. Paciltaxel Principle Practice Oncol. 10:1994;1-16.
10. Francis P.A., Kris M.G., Rigas J.R., Grant S.C., Miller V.A. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer. 12:1995;S163-S172.
11. Goldstein L.J. MDR1 gene expression in solid tumours. Eur. J. Cancer. 32:1996;1039-1050.
12. Hendrikse N.H., Franssen E.J., van-der-Graaf W.T., Vaalburg W., de-Vries E.G. Visualization of multidrug resistance in vivo. Eur. J. Nucl. Med. 26:1999;283-293.
13. Higgins C.F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8:1992;67-113.
14. Horwitz S.B., Cohen D., Rao S., Ringel I., Shen H.J., Yang C.P. Taxol: mechanism of action and resistance. J. Natl Cancer Inst. Monogr. 15:1993;55-61.
15. Horwitz S.B., Lothstein L., Manfredi J.J., Mellado W., Parness J., Roy S.N., Schiff P.B., Sorbara L., Zeheb R. Taxol: mechanisms of action and resistance. Ann. N.Y. Acad. Sci. 466:1986;733-744.
16. Hsu W.H., Yen R.F., Kao C.H., Shiun S.C., Hsu N.Y., Lin C.C., Lee C.C. Predicting chemotherapy responses to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (>T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein expression. Oncology. 63:2002;173-179.
17. Izquierdo M.A., Shoemaker R.H., Flens M.J., Scheffer G.L., Wu L., Prather T.R., Scheper R.J. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer. 65:1996;230-237.
18. Kao C.H., Hsieh J.F., Tsai S.C., Ho Y.J., ChangLai S.P., Lee J.K. Paclitaxel-based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging. J. Nucl. Med. 42:2001;17-20.
19. Kao C.H., Hsieh J.F., Tsai S.C., Ho Y.J., Lee J.K. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. Clin. Cancer Res. 6:2000;820-824.
20. Kitazono M., Sumizawa T., Takebayashi Y., Chen Z.S., Furukawa T., Nagayama S., Tani A., Takao S., Aikou T., Akiyama S. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J. Natl Cancer Inst. 91:1999;1647-1653.
21. Kostakoglu L., Kiratli P., Ruacan S., Hayran M., Emri S., Ergun E.L., Bekdik C.F. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J. Nucl. Med. 39:1998;228-234.
22. Liu B., Staren E.D., Iwamura T., Appert H.E., Howard J.M. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J. Surg. Res. 99:2001;179-186.
23. Oken M.M., Creech R.H., Tormey D.C. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655.
24. Paul D.M., Johnson D.H. Chemotherapy for non-small cell lung cancer. Johnson B.E., Johnson D.H. Lung Cancer. 1995;247-261 Wiley, New York.
25. Piwnica-Worms D., Chiu M.L., Budding M., Kronauge J.F., Kramer R.A., Croop J.M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 53:1993;977-984.
26. Scheper R.J., Broxterman H.J., Scheffer G.L., Kaaijk P., Dalton W.S., van Heijningen T.H., van Kalken C.K., Slovak M.L., de Vries E.G., van der Valk P. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53:1993;1457-1459.
27. Scheffer G.L., Wijngaard P.L., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J., Clevers H.C., Scheper R.J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 6:1995;578-582.
28. Shiau Y.C., Tsai S.C., Wang J.J., Ho Y.J., Ho S.T., Kao C.H. Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer. Lung. 179:2002;197-207.
29. Smit E.F., Postmus P.E. Chemotherapy of non-small cell lung cancer. Carney D.N. Lung Cancer. 1995;156-172 The Bath Press, Avon, London.
30. van-Ark-Otte J., Samelis G., Rubio G., Lopez-Saez J.B., Pinedo H.M., Giaccone G. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol. Rep. 5:1998;249-255.
31. Zhou J., Higashi K., Ueda Y., Kodama Y., Guo D., Jisaki F. Expression of multidrug resistance protein and messenger RNA correlate with 99mTc-MIBI imaging in patients with lung cancer. J. Nucl. Med. 42:2001;1476-1483.